7:20 am Coffee & Registration
8:25 am Chairs’ Opening Remarks
NAVIGATING NEXT-GENERATION ONCOLOGY MODELS: FROM MODELLING TUMOR MICROENVIRONMENT TO INTERROGATING MOA
8:30 am Optimizing IO Preclinical Research: GEMMs, CDX, PDX, Humanized Mouse Models or Organoids?
Synopsis
- Highlighting the key attributes of each model in the context of their specific research questions
- Strengthening linkages between preclinical and clinical development
- Maximizing current models while identifying appropriate prognostic and predictive biomarkers
9:00 am Leveraging Tumor Organoids & RWD to Generate Multimodal Insights for Drug Development
Synopsis
- Showcasing Tempus’ platform of 3D patient-derived organoids (PDOs) grounded in de-identified real-world clinical data to address high failure rates and increased costs in drug development due to a lack of robust preclinical models in the discovery and translational space
- With one of the largest, pan-indication PDO repositories in the industry, Tempus’ portfolio of fixed screening panels supports research questions across a range of modalities including small molecules, ADCs, and cell therapies
9:30 am Development of Image-based In vitro/In vivo Platform for Targeting CAFs
Synopsis
- Developing Image-based in vitro co-culture system to recapitulate the multicellular elements of TME, this allows monitoring of key cell-cell interactions between cancer cells, immune cells, and CAFs
- Developing multiple panels IVIS to better understand MOA of novel immune therapies
- Addressing the importance of using the right tumor cell line for investigating TME
10:00 am Navigating the Preclinical Oncology Landscape: The Search for Clinically Relevant PDX Models
10:30 am Speed Networking
Synopsis
Join our speed networking session tailored for preclinical and translational experts, like yourselves, to connect with industry peers & facilitating rapid yet meaningful exchanges of insights & expertise.
11:00 am Morning Break & Networking
Applications in Drug Discovery & Screening
Track Moderator: Regina Reilly, Research Fellow, Abbvie
11:30 am Optimizing Patient Representation Using PDX Models
Synopsis
- Addressing the ways to identify the best PDX models to use
- Understanding how to group PDX models
- Can fibrotic elements, extracellular matrix, and stroma be replicated using PDX models?
12:00 pm Identification of a SOCS1-edited TIL Therapy using CRISPR Screens in Mouse Syngeneic Tumor Models
Synopsis
- Demonstrating the power of CRISPR screens in syngeneic tumor models for immunotherapy target identification
- Highlighting the translatability of data generated in mouse models into human preclinical tumor models
Applications for Efficacy Evaluation & Biomarker Discovery
Track Moderator: Meghana Pandya, Senior Scientist, AstraZeneca
11:30 am In Vivo Imaging Biomarkers for Tumor Model Development & Understanding Mode of Action
Synopsis
- Preclinical imaging to understand tumor growth in orthotopic and GEMM models
- Development of bioluminescence reporter mouse models for visualizing and quantifying immune cells in vivo
- Clinically translatable imaging biomarkers in preclinical tumor models to understand mode of action
12:00 pm Leverage Single-Cell Multi-Omics for a Comprehensive Understanding of AML, PDX Model Validation, and Therapeutic Development
Synopsis
- Case studies leveraging single-cell DNA + protein multi-omics to understand AML disease evolution, treatment response, and mechanisms of resistance.
- How PDX models and sample multiplexing were used for baseline and end-point analysis in AML samples.
- Introducing a novel single-cell multiomics approach to dissect disease models, reduce downstream clinical trial costs and failure rates.
12:30 pm Lunch Break & Networking
1:30 pm Effectively Replicating the Tumor Stroma & Fibroblasts Using in vivo & in vitro Models
Synopsis
- Spotlighting advances in successfully mimicking the tumor stroma
- Reimagining drug discovery by recapitulating essential elements in tumor development
- How could we develop a model to address hypoxia?
2:00 pm Catalyzing Success, Unveiling the Power of Preclinical Models in PROTAC
Synopsis
- Introduction of a comprehensive platform for PROTAC evaluation
1:30 pm Mastermind Discussion: Increasing Clinical Translatability by Maximizing the Use of GEEMs
Synopsis
- Better recapitulating the genotype and phenotype of the disease with transgenic models
- Illustrating novel efficacy and safety data to evaluate the predictivity of using GEMMS
2:00 pm Myelofibrosis: A Challenging Preclinical Model with an Unmet Clinical Need – Presentation by TD2
Synopsis
- TD2 overview with updates in services and technology.
- General overview of myelofibrosis clinically and preclinically.
- TD2 models for myelofibrosis and how they can be used to drive programs forward
2:30 pm Afternoon Break & Networking
LEVERAGING NEW TECHNOLOGY & IN VIVO & IN VITRO MODELLING TO IMPROVE TRANSLATABILITY
3:00 pm In Pursuit of Precision: Clinical Relevance Makes All the Difference with CertisAI™ and Advanced Cancer Models
Synopsis
- Selecting an optimal artificial intelligence and machine learning platform for your drug discovery and development program: evaluation criteria to consider
- Exploring new CertisAI differentiators: it’s the first and only commercially available drug response and synergy platform that can predict therapeutic efficacy — requiring just a small molecule as input
- Reviewing new CertisAI in vivo validation study results using advanced orthotopic PDX models
- Analyzing new immunology study results, comparing differential immune responses and tumor infiltration in sub-Q versus orthotopic implantation for successful translation of T cell-based therapies into the clinic
3:30 pm How Can Physiologically Relevant 3D Tissue Models Be More Predictive of the Tumor Microenvironment?
Synopsis
- Assessing the role of the extracellular matrix and its importance in modeling the tumor microenvironment (TME)
- Enhancing spheroid stromal complexity using “MatriSpheres” to mimic tumor morphology and physical barriers within the TME
- Capturing tumor heterogeneity in vitro that reflects transcriptomic phenotypes of in vivo cancer cells
4:00 pm Humanized Mice for Oncology Drug Development
Synopsis
- Challenges in drug development using traditional oncology models
- Different types of humanized models for oncology drug development
4:30 pm Fire-Side Discussion: Evaluating Animal Models & Their Benefits in Testing Clinical Agents
Synopsis
- When should we still use mice in testing?
- The use of dogs for effectively demonstrating efficacy, toxicity, and impact from a clinical agent
- Leveraging monkeys for toxicity studies
- Delving into tissue cross-reactivity
5:00 pm Chair’s Closing Remarks
5:10 pm Tumor Models Drinks Reception & Poster Session
Synopsis
Join our dedicated drinks reception and poster session to connect with like-minded experts while gaining competitive insights from the innovative work submitted by your peers!